Cited by 616Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchAmyotrophic Lateral Sclerosis Research

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases

Open access

Lanoiselée, Hélène-Marie, Nicolas, Gaël, Wallon, David, Rovelet-Lecrux, Anne, Lacour, Morgane, Rousseau, Stéphane, Richard, Anne-Claire, Pasquier, Florence, Rollin-Sillaire, Adeline, Martinaud, Olivier, Quillard-Muraine, Muriel, de la Sayette, Vincent, Boutoleau-Bretonniere, Claire, Etcharry-Bouyx, Frédérique, Chauviré, Valérie, Sarazin, Marie, le Ber, Isabelle, Epelbaum, Stéphane, Jonveaux, Thérèse, Rouaud, Olivier, Ceccaldi, Mathieu, Félician, Olivier, Godefroy, Olivier, Formaglio, Maite, Croisile, Bernard, Auriacombe, Sophie, Chamard, Ludivine, Vincent, Jean-Louis, Sauvée, Mathilde, Marelli-Tosi, Cecilia, Gabelle, Audrey, Ozsancak, Canan, Pariente, Jérémie, Paquet, Claire, Hannequin, Didier, Campion, Dominique, collaborators of the CNR-MAJ project·2017·PLOS Medicine

DOI 10.1371/journal.pmed.1002270PMC PMC5370101

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Amyloid protein precursor (APP), presenilin-1 (PSEN1), and presenilin-2 (PSEN2) mutations cause autosomal dominant forms of early-onset Alzheimer disease (AD-EOAD). Although these genes were identified in the 1990s, variant classification remains a challenge, highlighting the need to colligate mutations from large series. METHODS AND FINDINGS: We report here a novel update (2012-2016) of the genetic screening of the large AD-EOAD series ascertained across 28 French hospitals from 1993 onwards, bringing the total number of families with identified mutations to n = 170. Families were included when at least two first-degree relatives suffered from early-onset Alzheimer disease (EOAD) with an age of onset (AOO) ≤65 y in two generations. Furthermore, we also screened 129 sporadic cases of Alzheimer disease with an AOO below age 51 (44% males, mean AOO = 45 ± 2 y). APP, PSEN1, or PSEN2 mutations were identified in 53 novel AD-EOAD families. Of the 129 sporadic cases screened, 17 carried a PSEN1 mutation and 1 carried an APP duplication (13%). Parental DNA was available for 10 sporadic mutation carriers, allowing us to show that the mutation had occurred de novo in each case. Thirteen mutations (12 in PSEN1 and 1 in PSEN2) identified either in familial or in sporadic cases were previously unreported. Of the 53 mutation carriers with available cerebrospinal fluid (CSF) biomarkers, 46 (87%) had all three CSF biomarkers-total tau protein (Tau), phospho-tau protein (P-Tau), and amyloid β (Aβ)42-in abnormal ranges. No mutation carrier had the three biomarkers in normal ranges. One limitation of this study is the absence of functional assessment of the possibly and probably pathogenic variants, which should help their classification. CONCLUSIONS: Our findings suggest that a nonnegligible fraction of PSEN1 mutations occurs de novo, which is of high importance for genetic counseling, as PSEN1 mutational screening is currently performed in familial cases only. Among the 90 distinct mutations found in the whole sample of families and isolated cases, definite pathogenicity is currently established for only 77%, emphasizing the need to pursue the effort to classify variants.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1371/journal.pmed.1002270

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Analysis of protein-coding genetic variation in 60,706 humans
Exome Aggregation Consortium, Lek, M., Karczewski, K. J., Minikel, E. V., Samocha, K. E., Banks, E., Fennell, T., O’Donnell-Luria, A. H., Ware, J. S., Hill, A. J., et al. (2016) · Nature · doi:10.1038/nature19057 · Cited by 9,587
Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy
Rovelet‐Lecrux, A., Hannequin, D., Raux, G., Meur, N. L., Laquerrière, A., Vital, A., Dumanchin‐Njock, C., Feuillette, S., Brice, A., Vercelletto, M., et al. (2005) · Nature Genetics · doi:10.1038/ng1718 · Cited by 1,284
Self-citation
Early-onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene
Chartier-Harlin, M.-C., Crawford, F., Houlden, H., Warren, A., Hughes, D., Fidani, L., Goate, A., Rossor, M., Roques, P., Hardy, J., et al. (1991) · Nature · doi:10.1038/353844a0 · Cited by 1,214
Trafficking and Proteolytic Processing of APP
Haass, C., Kaether, C., Thinakaran, G., & Sisodia, S. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006270 · Cited by 1,075
A framework for the interpretation of de novo mutation in human disease
Samocha, K. E., Robinson, E. B., Sanders, S. J., Stevens, C., Sabo, A., McGrath, L. M., Kosmicki, J. A., Rehnström, K., Mallick, S., Kirby, A., et al. (2014) · Nature Genetics · doi:10.1038/ng.3050 · Cited by 979
A Familial Alzheimer's Disease Locus on Chromosome 1
Levy‐Lahad, E., Wijsman, E. M., Nemens, E. J., Anderson, L., Goddard, K. A. B., Weber, J. L., Bird, T. D., & Schellenberg, G. D. (1995) · Science · doi:10.1126/science.7638621 · Cited by 832

Show all 44 references

Sorted by citations

Items 201–300 of 614

A microglia clonal inflammatory disorder in Alzheimer’s disease
Vicario, R., Fragkogianni, S., Weber, L., Lazarov, T., Hu, Y., Hayashi, S. Y., Craddock, B., Socci, N. D., Alberdi, A., Baako, A., et al. (2025) · eLife · doi:10.7554/elife.96519.3 · Cited by 21
Estimation of genomic instability and mutation induction by graphene oxide nanoparticles in mice liver and brain tissues
Mohamed, H. R. H., Welson, M., Yaseen, A. E., & El-Ghor, A. A. (2019) · Environmental Science and Pollution Research · doi:10.1007/s11356-019-06930-0 · Cited by 21
Genetic testing in dementia‐A medical genetics perspective
Huq, A. J., Sexton, A., Lacaze, P. A., Masters, C. L., Storey, E., Velakoulis, D., James, P. A., & Winship, I. (2021) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.5535 · Cited by 23
Network-guided analysis of hippocampal proteome identifies novel proteins that colocalize with Aβ in a mice model of early-stage Alzheimer’s disease
Aladeokin, A. C., Akiyama, T. H., Kimura, A., Kimura, Y., Jitsuki‐Takahashi, A., Nakamura, H., Makihara, H., Masukawa, D., Nakabayashi, J., Hirano, H., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104603 · Cited by 23
Human-Induced Neurons from Presenilin 1 Mutant Patients Model Aspects of Alzheimer’s Disease Pathology
Schrank, S., McDaid, J., Briggs, C. A., Mustaly-Kalimi, S., Brinks, D., Houcek, A., Singer, O., Bottero, V., Marr, R. A., & Stutzmann, G. E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031030 · Cited by 22
Formaldehyde‐Crosslinked Nontoxic Aβ Monomers to Form Toxic Aβ Dimers and Aggregates: Pathogenicity and Therapeutic Perspectives
Zhao, H., Huang, X., & Tong, Z. (2021) · ChemMedChem · doi:10.1002/cmdc.202100428 · Cited by 21
Brain-Gut and Microbiota-Gut-Brain Communication in Type-2 Diabetes Linked Alzheimer’s Disease
Momen, Y. S., Mishra, J., & Kumar, N. (2024) · Nutrients · doi:10.3390/nu16152558 · Cited by 26
The Therapeutic Potential of Butyrate and Lauric Acid in Modulating Glial and Neuronal Activity in Alzheimer’s Disease
Wtpsk, S., Oikari, L. E., Bharadwaj, P., Jayasena, V., Martins, R. N., & Fernando, W. M. A. D. B. (2025) · Nutrients · doi:10.3390/nu17142286 · Cited by 23
Clearance of β‐amyloid mediated by autophagy is enhanced by MTORC1 inhibition but not AMPK activation in APP / PSEN1 astrocytes
García‐Juan, M., Ordóñez‐Gutiérrez, L., & Wandosell, F. G. (2023) · Glia · doi:10.1002/glia.24492 · Cited by 21
Imbalance in the response of pre- and post-synaptic components to amyloidopathy
Stephen, T., Tamagnini, F., Piegsa, J., Sung, K., Harvey, J., Oliver‐Evans, A., Murray, T. K., Ahmed, Z., Hutton, M. L., Randall, A. D., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-50781-1 · Cited by 23
Genetics of Alzheimer Disease
Jayadev, S. (2022) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001125 · Cited by 21
CRISPR–Cas technologies in neurodegenerative disorders: mechanistic insights, therapeutic potential, and translational challenges
Yashooa, R. K., Nabi, A. Q., Smail, S. W., Azeez, S. S., Nooh, W. A., Mustafa, S. A., Al-Farha, A. A.-B., Capitanio, N., & Shekha, M. S. (2026) · Frontiers in Neurology · doi:10.3389/fneur.2025.1737468 · Cited by 21
A novel mutation in PSEN1 (p.T119I) in an Argentine family with early- and late-onset Alzheimer's disease
Itzcovich, T., Chrem-Méndez, P., Vázquez, S., Kennedy, M. B., Niikado, M., Martinetto, H., Allegri, R., Sevlever, G. E., & Surace, E. I. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.05.001 · Cited by 19
Phenotype and imaging features associated with APP duplications
Grangeon, L., Charbonnier, C., Zaréa, A., Rousseau, S., Rovelet‐Lecrux, A., Bendetowicz, D., Lemaitre, M., Malrain, C., Quillard‐Muraine, M., Cassinari, K., et al. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01172-2 · Cited by 18
Self-citation
Longitudinal clinical, cognitive and biomarker profiles in dominantly inherited versus sporadic early-onset Alzheimer’s disease
Llibre‐Guerra, J. J., Iaccarino, L., Coble, D., Edwards, L., Li, Y., McDade, E., Strom, A., Gordon, B. A., Mundada, N. S., Schindler, S. E., et al. (2023) · Brain Communications · doi:10.1093/braincomms/fcad280 · Cited by 21
GLP-1/Sigma/RAGE receptors: An evolving picture of Alzheimer's disease pathology and treatment
Neha, N., Wali, Z., Pinky, P., Hattiwale, S. H., Jamal, A., & Parvez, S. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102134 · Cited by 19
Pathological Involvement of Protein Phase Separation and Aggregation in Neurodegenerative Diseases
Wu, Y.-F., Ma, B., Liu, C. Y., Li, D., & Sui, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251810187 · Cited by 21
An Analysis of the Neurological and Molecular Alterations Underlying the Pathogenesis of Alzheimer’s Disease
Vidal, C., & Li, Z. (2021) · Cells · doi:10.3390/cells10030546 · Cited by 20
Amyloid precursor protein intracellular domain-dependent regulation of FOXO3a inhibits adult hippocampal neurogenesis
Jiang, M. H., Vanan, S., Tu, H., Zhang, W., Zhang, Z.-W., Chia, S., Jang, S. E., Zeng, X., Yu, W., Xu, J., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.07.031 · Cited by 19
Contribution of Extracellular Vesicles and Molecular Chaperones in Age-Related Neurodegenerative Disorders of the CNS
Noori, L., Filip, K., Nazmara, Z., Mahakizadeh, S., Hassanzadeh, G., Bavisotto, C. C., Bucchieri, F., Marino, A., Cappello, F., Wnuk, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24020927 · Cited by 18
Recent advances in Alzheimer disease genetics
Nicolas, G. (2024) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001242 · Cited by 19
Self-citation
14‐3‐3 Family of Proteins: Biological Implications, Molecular Interactions, and Potential Intervention in Cancer, Virus and Neurodegeneration Disorders
Low, Z. Y., Yip, A. J. W., Chan, A. M. L., & Choo, W. S. (2024) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30624 · Cited by 20
Exome sequencing revealed PDE11A as a novel candidate gene for early-onset Alzheimer’s disease
Qin, W., Zhou, A., Zuo, X., Jia, L., Wei, C., Wang, Q., Wang, F., Li, F., Wang, Q., Li, Y., et al. (2021) · Human Molecular Genetics · doi:10.1093/hmg/ddab090 · Cited by 16
Associations of the APOE ε2 and ε4 alleles and polygenic profiles comprising APOE-TOMM40-APOC1 variants with Alzheimer’s disease biomarkers
Kulminski, A. M., Initiative, A. D. N., Jain‐Washburn, E., Loiko, E., Loika, Y., Feng, F., & Culminskaya, I. V. (2022) · Aging · doi:10.18632/aging.204384 · Cited by 17
Evolutionary and genomic perspectives of brain aging and neurodegenerative diseases
Dames, B. A. R., Kilili, H., Charvet, C. J., Díaz-Barba, K., Proulx, M. J., de Sousa, A. A., & Urrutia, A. O. (2023) · Progress in brain research · doi:10.1016/bs.pbr.2022.10.004 · Cited by 18
E674Q (Shanghai APP mutant), a novel amyloid precursor protein mutation, in familial late-onset Alzheimer's disease
Zhang, Y., Xie, X., Chen, B., Pan, L., Li, J., Wang, W., Wang, J., Tang, R., Huang, Q., Chen, X., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.02.051 · Cited by 19
Outdoor artificial light at night and risk of early-onset dementia: A case-control study in the Modena population, Northern Italy
Mazzoleni, E., Vinceti, M., Costanzini, S., Garuti, C., Adani, G., Vinceti, G., Zamboni, G., Tondelli, M., Galli, C., Salemme, S., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e17837 · Cited by 18
Alzheimer’s disease-related presenilins are key to intestinal epithelial cell function and gut immune homoeostasis
Erkert, L., Gámez‐Belmonte, R., Kabisch, M., Schödel, L., Patankar, J. V., González-Acera, M., Mahapatro, M., Bao, L., Plattner, C., Kühl, A. A., et al. (2024) · Gut · doi:10.1136/gutjnl-2023-331622 · Cited by 17
Harnessing artificial intelligence in Alzheimer's disease management: navigating ethical challenges in AI
Habibi, F., Ghaderkhani, S., Shokoohi, M., Banari, T., Morsali, M., Abadi, R. N. S., & Kiamehr, H. (2025) · AI and Ethics · doi:10.1007/s43681-025-00673-0 · Cited by 19
Mutant Presenilin 1 Dysregulates Exosomal Proteome Cargo Produced by Human-Induced Pluripotent Stem Cell Neurons
Podvin, S., Jones, A. C., Liu, Q., Aulston, B. D., Mosier, C., Ames, J., Winston, C. N., Lietz, C. B., Jiang, Z., O’Donoghue, A. J., et al. (2021) · ACS Omega · doi:10.1021/acsomega.1c00660 · Cited by 16
Neuroepigenetic Mechanisms of Action of Ultrashort Peptides in Alzheimer’s Disease
Ilina, A., Khavinson, V., Linkova, N. S., & Petukhov, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084259 · Cited by 18
Targeting of Disordered Proteins by Small Molecules in Neurodegenerative Diseases
Longhena, F., Spano, P., & Bellucci, A. (2017) · Handbook of experimental pharmacology · doi:10.1007/164_2017_60 · Cited by 17
Gene surgery
El-Kenawy, A. E.-M., Benarba, B., Neves, A. F., Araújo, T. G., Tan, B. L., & Gouri, A. (2019) · EXCLI journal · doi:10.17179/excli2019-1833 · Cited by 16
Unraveling the Complexity of Alzheimer’s Disease: Insights into Etiology and Advancements in Treatment Strategies
Khan, B., Iqbal, M. K., Khan, M. A., Khan, H. R., Kiyani, M. M., Bashir, S., & Li, S. (2025) · Journal of Molecular Neuroscience · doi:10.1007/s12031-025-02337-4 · Cited by 17
A review on synthetic inhibitors of dual-specific tyrosine phosphorylation-regulated kinase 1A (DYRK1A) for the treatment of Alzheimer’s disease (AD)
Gehlot, P., Pathak, R., Kumar, S., Choudhary, N. K., & Vyas, V. K. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117925 · Cited by 18
Olive Oil Industry By-Products as a Novel Source of Biophenols with a Promising Role in Alzheimer Disease Prevention
Gonçalves, M., Costa, M., Paiva‐Martins, F., & Silva, P. (2024) · Molecules · doi:10.3390/molecules29204841 · Cited by 17
BaiHui: cross-species brain-specific network built with hundreds of hand-curated datasets
Li, H., Bai, T., Sandford, E., Burmeister, M., & Guan, Y. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty1001 · Cited by 16
Shared (epi)genomic background connecting neurodegenerative diseases and type 2 diabetes
Caputo, V., Termine, A., Strafella, C., Giardina, E., & Cascella, R. (2020) · World Journal of Diabetes · doi:10.4239/wjd.v11.i5.155 · Cited by 17
Two Novel Mutations and a de novo Mutation in PSEN1 in Early-onset Alzheimer’s Disease
Li, Y., Yang, Z.-H., Zhang, Y., Yang, J., Shang, D., Zhang, S., Wu, J. W., Ji, Y., Zhao, L., Shi, C., et al. (2018) · Aging and Disease · doi:10.14336/ad.2018.1109 · Cited by 16
Structural Proteomic Profiling of Cerebrospinal Fluids to Reveal Novel Conformational Biomarkers for Alzheimer’s Disease
Wang, B., Zhong, X., Fields, L. G., Lu, H., Zhu, Z., & Li, L. (2023) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.2c00332 · Cited by 15
Presenilin-1-Derived Circular RNAs: Neglected Epigenetic Regulators with Various Functions in Alzheimer’s Disease
Sanadgol, N., Amini, J., Beyer, C., & Zendedel, A. (2023) · Biomolecules · doi:10.3390/biom13091401 · Cited by 15
Spatial–Temporal Mapping Reveals the Golgi as the Major Processing Site for the Pathogenic Swedish APP Mutation: Familial APP Mutant Shifts the Major APP Processing Site
Wang, J., Gleeson, P. A., & Fourrière, L. (2024) · Traffic · doi:10.1111/tra.12932 · Cited by 17
Identification and characterization of variants in PSEN1, PSEN2, and APP genes in Chinese patients with early-onset Alzheimer's disease
Nan, H., Chu, M. K., Jiang, D., Liang, W., Li, Y., Wu, Y., Wang, Z., & Wu, L. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01702-0 · Cited by 17
Impaired proteostasis in rare neurological diseases
Osinalde, N., Duarri, A., Ramírez, J., Barrio, R., de Nanclares, G. P., & Mayor, U. (2018) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2018.10.007 · Cited by 19
Genetic Study of Alzheimer’s Disease in Saudi Population
Bitar, F. E., Qadi, N., Rajeh, S. A., Majrashi, A., Abdulaziz, S., Majrashi, N., Inizi, M. A., Taher, A., & Tassan, N. A. A. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180415 · Cited by 14
Analysis of dementia-related gene variants in APOE ε4 noncarrying Korean patients with early-onset Alzheimer's disease
Park, J. E., Kim, H. J., Kim, Y.-E., Jang, H., Cho, S. H., Kim, S. J., Na, D. L., Won, H., Ki, C., & Seo, S. W. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.05.009 · Cited by 15
CRISPR/Cas9 Technology as a Modern Genetic Manipulation Tool for Recapitulating of Neurodegenerative Disorders in Large Animal Models
Barazesh, M., Mohammadi, S., Bahrami, Y., Mokarram, P., Morowvat, M. H., Saidijam, M., Karimipoor, M., Kavousipour, S., Vosoughi, A. R., & Khanaki, K. (2020) · Current Gene Therapy · doi:10.2174/1566523220666201214115024 · Cited by 19
Exosomes in Age-Related Cognitive Decline: Mechanistic Insights and Improving Outcomes
Duggan, M. R., Lu, A., Foster, T. C., Wimmer, M. E., & Parikh, V. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.834775 · Cited by 15
Characterizing dysregulations via cell-cell communications in Alzheimer’s brains using single-cell transcriptomes
Lee, C.-Y., Riffle, D., Xiong, Y., Momtaz, N., Lei, Y., Pariser, J. M., Sikdar, D., Hwang, A., Duan, Z., & Zhang, J. (2024) · BMC Neuroscience · doi:10.1186/s12868-024-00867-y · Cited by 17
RNA‐Based Therapies for Neurodegenerative Diseases Targeting Pathogenic Proteins
Rabbani, S. A., El‐Tanani, M., Sharma, S., El‐Tanani, Y., Kumar, R., Saini, M., Yadav, M., Khan, M. A., & Parvez, S. (2025) · European Journal of Neuroscience · doi:10.1111/ejn.70110 · Cited by 15
Clinical impact of whole-genome sequencing in patients with early-onset dementia
Huq, A. J., Thompson, B. A., Bennett, M. F., Bournazos, A., Bommireddipalli, S., Gorelik, A., Schultz, J. R., Sexton, A., Purvis, R., West, K., et al. (2022) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2021-328146 · Cited by 14
A Rare Variation in the 3’ Untranslated Region of the Presenilin 2 Gene Is Linked to Alzheimer’s Disease
Pang, Y., Li, T., Wang, Q., Qin, W., Li, Y., Wei, Y., & Jia, L. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02429-3 · Cited by 13
Copy Number Variation Identification on 3,800 Alzheimer’s Disease Whole Genome Sequencing Data from the Alzheimer’s Disease Sequencing Project
Lee, W., Tucci, A. A., Conery, M., Leung, Y. Y., Kuzma, A. B., Valladares, O., Chou, Y., Lu, W., Wang, L., Schellenberg, G. D., et al. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.752390 · Cited by 14
OCT Imaging in Murine Models of Alzheimer’s Disease in a Systematic Review: Findings, Methodology and Future Perspectives
Sánchez-Puebla, L., López‐Cuenca, I., Salobrar‐García, E., Ramirez, A. I., Fernández‐Albarral, J. A., Matamoros, J. A., Elvira‐Hurtado, L., Salazar, J. J., Ramirez, J. M., & de Hoz, R. (2024) · Biomedicines · doi:10.3390/biomedicines12030528 · Cited by 14
Genomic Insights into Dementia: Precision Medicine and the Impact of Gene-Environment Interaction
Tripathi, A., Pandey, V. K., Sharma, G., Sharma, A. R., Taufeeq, A., Jha, A. K., & Kim, J. (2024) · Aging and Disease · doi:10.14336/ad.2024.0322 · Cited by 13
Novel techniques for early diagnosis and monitoring of Alzheimer’s disease
Parul, P., Singh, A. K., & Shukla, S. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2415985 · Cited by 13
Sex-related differences in genetically determined Alzheimer’s disease
Soriano, L. D. H., Wagemann, O., Bejanin, A., Levin, J., & Fortea, J. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1522434 · Cited by 16
Identification of a novel PSEN1 Gly111Val missense mutation in a Chinese pedigree with early-onset Alzheimer's disease
Qiu, Q., Jia, L., Wang, Q., Zhao, L., Jin, H., Li, T., Quan, M., Xu, L., Li, B., Li, Y., et al. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.05.018 · Cited by 13
The relationship of early- and late-onset Alzheimer’s disease genes with COVID-19
Şirin, S., Dolanbay, S. N., & Aslım, B. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-022-02499-0 · Cited by 13
The Impact of APOE ɛ 4 in Alzheimer’s Disease Differs According to Age
Kim, J., Park, S., Yoo, H., Jang, H., Kim, Y., Kim, K. W., Jang, Y. K., Lee, J. S., Kim, S. T., Kim, S., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170556 · Cited by 15
Targeting Inflammation in Alzheimer’s Disease: Insights Into Pathophysiology and Therapeutic Avenues-A Comprehensive Review
Topalis, V., Voros, C., & Ziaka, M. (2025) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/08919887251361578 · Cited by 14
Tailoring the biomarkers of Alzheimer’s disease using a gut microbiome-centric approach: Preclinical, clinical, and regulatory perspectives
Sharma, S., Bashir, B., Kolekar, K. A., Acharya, A., Gupta, M., Jena, R., Vishwas, S., Kaur, J., Gupta, G., Kumbhar, P., et al. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102888 · Cited by 15
Recent advances in potential enzymes and their therapeutic inhibitors for the treatment of Alzheimer's disease
Vahid, Z. F., Eskandani, M., Dadashi, H., Vandghanooni, S., & Rashidi, M. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e40756 · Cited by 14
Proteomic Insight Into Alzheimer's Disease Pathogenesis Pathways
Ryu, T., Kim, K., Asiimwe, N., & Na, C. H. (2025) · PROTEOMICS · doi:10.1002/pmic.202400298 · Cited by 12
Unveiling exosomal biomarkers in neurodegenerative diseases: LC-MS-based profiling
Bi, Y.-L., Wang, L., Li, C., Shan, Z. J., & Bi, L. (2025) · Extracellular Vesicle · doi:10.1016/j.vesic.2025.100071 · Cited by 13
Excessive Alcohol Use as a Risk Factor for Alzheimer’s Disease: Epidemiological and Preclinical Evidence
Anton, P. E., Maphis, N. M., Linsenbardt, D. N., & Coleman, L. G. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-81908-7_10 · Cited by 12
Identification of missing variants by combining multiple analytic pipelines
Ren, Y., Reddy, J. S., Pottier, C. P., Sarangi, V., Tian, S., Sinnwell, J. P., McDonnell, S. K., Biernacka, J. M., Carrasquillo, M. M., Ross, O. A., et al. (2018) · BMC Bioinformatics · doi:10.1186/s12859-018-2151-0 · Cited by 12
Identification of Somatic Mutations in Dementia-related Genes in Cancer Patients
Kim, Y., & Jeong, B. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666201203124341 · Cited by 12
Genetic study of young‐onset dementia using targeted gene panel sequencing in Taiwan
Hsu, J., Lin, C., Chen, P., Lin, K., & Chen, T. (2021) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32836 · Cited by 12
Clinical Phenotype and Mutation Spectrum of Alzheimer’s Disease with Causative Genetic Mutation in a Chinese Cohort
Mao, C., Li, J., Dong, L., Huang, X., Lei, D., Wang, J., Chu, S., Liu, C., Peng, B., Román, G. C., et al. (2021) · Current Alzheimer Research · doi:10.2174/1567205018666210608120339 · Cited by 12
The Clinical Spectrum of Young Onset Dementia Points to Its Stochastic Origins
Panegyres, P. K. (2021) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-210309 · Cited by 12
A novel approach to type 3 diabetes mechanism: The interplay between noncoding RNAs and insulin signaling pathway in Alzheimer's disease
Moayedi, K., Orandi, S., Ebrahimi, R., Tanhapour, M., Moradi, M., Abbastabar, M., & Golestani, A. (2022) · Journal of Cellular Physiology · doi:10.1002/jcp.30779 · Cited by 12
Does Dementia Have a Microbial Cause?
Landry, R. L., & Embers, M. E. (2022) · NeuroSci · doi:10.3390/neurosci3020019 · Cited by 14
Neuroinflammation drives APOE genotype-dependent differential expression of neprilysin
Graykowski, D. R., Kasparian, K., Caniglia, J. L., Gritsaeva, Y., & Cudaback, E. (2020) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2020.577315 · Cited by 12
Systems biology of Alzheimer’s Disease: a scoping review of key pathways and mechanisms
Bice, P. J., Nho, K. T., Ertekin‐Taner, N., & Saykin, A. J. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00934-4 · Cited by 14
Large-scale gene expression changes in APP/PSEN1 and GFAP mutation models exhibit high congruence with Alzheimer’s disease
Gammie, S. C., Messing, A., Hill, M. A., Kelm‐Nelson, C. A., & Hagemann, T. L. (2024) · PLoS ONE · doi:10.1371/journal.pone.0291995 · Cited by 11
Pathophysiological role of high mobility group box-1 signaling in neurodegenerative diseases
Kumar, V., & Kumar, P. (2024) · Inflammopharmacology · doi:10.1007/s10787-024-01595-9 · Cited by 11
Light at night exposure and risk of dementia conversion from mild cognitive impairment in a Northern Italy population
Filippini, T., Costanzini, S., Chiari, A., Urbano, T., Despini, F., Tondelli, M., Bedin, R., Zamboni, G., Teggi, S., & Vinceti, M. (2024) · International Journal of Health Geographics · doi:10.1186/s12942-024-00384-5 · Cited by 11
Bioinformatics and Deep Learning Approach to Discover Food-Derived Active Ingredients for Alzheimer’s Disease Therapy
Zhou, J., Li, C., Kim, Y. K., & Park, S. (2025) · Foods · doi:10.3390/foods14010127 · Cited by 11
Gene therapy-mediated enhancement of protective protein expression for the treatment of Alzheimer’s disease
Owens, L., Benedetto, A., Dawson, N., Gaffney, C. J., & Parkin, E. T. (2021) · Brain Research · doi:10.1016/j.brainres.2020.147264 · Cited by 11
Generation of induced pluripotent stem cells (IRMBi001-A) from an Alzheimer's disease patient carrying a G217D mutation in the PSEN1 gene
Auboyer, L., Monzo, C., Wallon, D., Rovelet‐Lecrux, A., Gabelle, A., Gazagne, I., Cacheux, V., Lehmann, S., & Crozet, C. (2019) · Stem Cell Research · doi:10.1016/j.scr.2018.101381 · Cited by 11
Self-citation
Mutation Analysis of the Genes Linked to Early Onset Alzheimer’s Disease and Frontotemporal Lobar Degeneration
Luukkainen, L., Helisalmi, S., Kytövuori, L., Ahmasalo, R., Solje, E., Haapasalo, A., Hiltunen, M., Remes, A. M., & Krüger, J. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181256 · Cited by 11
Language impairment in primary progressive aphasia and other neurodegenerative diseases
Rahul, D. R., & Ponniah, R. J. (2019) · Journal of Genetics · doi:10.1007/s12041-019-1139-5 · Cited by 11
Contributions of Molecular and Optical Techniques to the Clinical Diagnosis of Alzheimer’s Disease
Bistaffa, E., Tagliavini, F., Matteini, P., & Moda, F. (2020) · Brain Sciences · doi:10.3390/brainsci10110815 · Cited by 11
Structural Predictive Model of Presenilin-2 Protein and Analysis of Structural Effects of Familial Alzheimer’s Disease Mutations
Soto-Ospina, A., Marín, P. A., Bedoya, G., & Lanau, A. V. (2021) · Biochemistry Research International · doi:10.1155/2021/9542038 · Cited by 14
Are Hippocampal Hypoperfusion and ATP Depletion Prime Movers in the Genesis of Alzheimer’s Disease? A Review of Recent Pertinent Observations from Molecular Biology
Walker, V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157328 · Cited by 11
RyR2‐dependent modulation of neuronal hyperactivity: A potential therapeutic target for treating Alzheimer's disease
Yao, J., & Chen, S. R. W. (2023) · The Journal of Physiology · doi:10.1113/jp283824 · Cited by 10
A strategic tool to improve the study of molecular determinants of Alzheimer’s disease: The role of glyceraldehyde
Piccirillo, S., Preziuso, A., Cerqueni, G., Serfilippi, T., Terenzi, V., Vinciguerra, A., Amoroso, S., Lariccia, V., & Magi, S. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115869 · Cited by 10
The Role of RIN3 Gene in Alzheimer’s Disease Pathogenesis: a Comprehensive Review
Meshref, M. M., Ghaith, H. S., Hammad, M. A., Shalaby, M. M. M., Ayasra, F., Monib, F. A., Attia, M. S., Ebada, M. A., Elsayed, H., Shalash, A., et al. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03802-0 · Cited by 12
Predicting disease-gene associations through self-supervised mutual infomax graph convolution network
Xie, J., Rao, J., Xie, J., Zhao, H., & Yang, Y. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.108048 · Cited by 11
Molecular neuroimaging in dominantly inherited versus sporadic early-onset Alzheimer’s disease
Iaccarino, L., Llibre‐Guerra, J. J., McDade, E., Edwards, L., Gordon, B. A., Benzinger, T. L. S., Hassenstab, J. J., Kramer, J. H., Li, Y., Miller, B. L., et al. (2024) · Brain Communications · doi:10.1093/braincomms/fcae159 · Cited by 11
A multifactorial lens on risk factors promoting the progression of Alzheimer’s disease
Parker, J., Moris, J. M., Goodman, L. C., Paidisetty, V. K., Vanegas, V., Turner, H. A., Melgar, D., & Koh, Y. (2024) · Brain Research · doi:10.1016/j.brainres.2024.149262 · Cited by 12
Integrating rare pathogenic variant prioritization with gene‐based association analysis to identify novel genes and relevant multimodal traits for Alzheimer's disease
Cao, J., Zhang, C., Lo, C. Z., Guo, Q., Ding, J., Luo, X., Zhang, Z., Chen, F., Cheng, T., Chen, J., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14444 · Cited by 11
Computational and functional prioritization identifies genes that rescue behavior and reduce tau protein in fly and human cell models of Alzheimer disease
Stephens, M. C., Li, J., Mair, M. L., Moore, J., Zhu, K. F., Tarkunde, A., Amoh, B. K., Perez, A. M., Bhakare, A., Guo, F., et al. (2025) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2025.03.012 · Cited by 9
Intervention points for the role of physical activity in prevention and treatment of Alzheimer's disease
Brendborg, N., & Febbraio, M. A. (2025) · The Journal of Physiology · doi:10.1113/jp286747 · Cited by 10
Identification of Potential Driver Genes and Pathways Based on Transcriptomics Data in Alzheimer's Disease
Xia, L.-Y., Tang, L., Huang, H., & Luo, J. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.752858 · Cited by 11
Precision Medicine: Role of Biomarkers in Early Prediction and Diagnosis of Alzheimer’s Disease
Shen, L., Xia, S., Zhang, H., Yao, F., Liu, X., Zhao, Y., Ying, M., Iqbal, J., & Liu, Q. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.82035 · Cited by 9
Correlation of [18F]florbetaben textural features and age of onset of Alzheimer’s disease: a principal components analysis approach
Li, J., Antonecchia, E., Camerlenghi, M., Chiaravalloti, A., Chu, Q., Costanzo, A. D., Li, Z., Wan, L., Zhang, X., D’Ascenzo, N., et al. (2021) · EJNMMI Research · doi:10.1186/s13550-021-00774-x · Cited by 10
Exercise Reverses Amyloid β-Peptide–Mediated Cognitive Deficits in Alzheimer’s Disease Mice Expressing Mutant Presenilin-2
Hwang, D.-J., Choi, D.-H., Kwon, K.-C., Kim, E., Kim, T., Koo, J., & Cho, J. (2021) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000002834 · Cited by 10
Elucidation of the neurological effects of clothianidin exposure at the no-observed-adverse-effect level (NOAEL) using two-photon microscopy in vivo imaging
NISHI, M., Sugio, S., Hirano, T., Kato, D., Wake, H., SHODA, A., MURATA, M., Ikenaka, Y., Tabuchi, Y., MANTANI, Y., et al. (2022) · Journal of Veterinary Medical Science · doi:10.1292/jvms.22-0013 · Cited by 10

Authors: Lanoiselée, H.-M., Nicolas, G., Wallon, D., Rovelet-Lecrux, A., Lacour, M., Rousseau, S., Richard, A.-C., Pasquier, F., Rollin-Sillaire, A., Martinaud, O., Quillard-Muraine, M., de la Sayette, V., Boutoleau-Bretonniere, C., Etcharry-Bouyx, F., Chauviré, V., Sarazin, M., le Ber, I., Epelbaum, S., Jonveaux, T., Rouaud, O., Ceccaldi, M., Félician, O., Godefroy, O., Formaglio, M., Croisile, B., Auriacombe, S., Chamard, L., Vincent, J.-L., Sauvée, M., Marelli-Tosi, C., Gabelle, A., Ozsancak, C., Pariente, J., Paquet, C., Hannequin, D., Campion, D., & collaborators of the CNR-MAJ project
Affiliations: Inserm (FR)
Centre Hospitalier Universitaire d'Angers (FR)
Centre Hospitalier Sainte-Anne (FR)
Centre National de la Recherche Scientifique (FR)
Centre Hospitalier Régional et Universitaire de Nancy (FR)
CHU Dijon Bourgogne (FR)
Centre Hospitalier Universitaire Amiens-Picardie (FR)
Hospices Civils de Lyon (FR)
Centre Hospitalier Universitaire de Bordeaux (FR)
Centre Hospitalier Universitaire de Lille (FR)
Centre Hospitalier Universitaire de Grenoble (FR)
Centre Hospitalier Universitaire de Montpellier (FR)
Centre Hospitalier Universitaire de Toulouse (FR)
Corresponding author: Campion, Dominique
ORCID: Nicolas, Gaël
Wallon, David
Pasquier, Florence
Sarazin, Marie
Epelbaum, Stéphane
Jonveaux, Thérèse
Rouaud, Olivier
Ceccaldi, Mathieu
Félician, Olivier
Godefroy, Olivier
Croisile, Bernard
Sauvée, Mathilde
Gabelle, Audrey
Pariente, Jérémie
Paquet, Claire
Hannequin, Didier
Campion, Dominique
Venue: PLOS Medicine
Publisher: Public Library of Science (PLoS)
Published: 2017-03-28
Volume: 14
Issue: 3
Pages: e1002270
ISSN: 1549-1277 (ISSN-L)
1549-1676
DOI: 10.1371/journal.pmed.1002270
PMC: PMC5370101
OpenAlex: W2600872530
Cited by: 616
References: 44
Citations by year: 2026: 58 · 2025: 102 · 2024: 94 · 2023: 75 · 2022: 79 · 2021: 64 · 2020: 58 · 2019: 41 · 2018: 34 · 2017: 9
FWCI: 28.74
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
creativecommons.org/licenses/by/4.0/ (vor)
Locations: PLoS Medicine (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
HAL (submittedVersion, cc-by)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Figshare (submittedVersion, cc-by)
LillOA (Université de Lille (University Of Lille)) (submittedVersion, cc-by)
Funders: Clinical Research Hospital Program from the French Ministry of Health (GMAJ 2008/067)
French Ministry of Health (CNR-MAJ)
European Union (JPND PERADES, ANR-13-JPRF-0001-04)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
Keywords: early-onset Alzheimer's disease, APP mutations, PSEN1 mutations, PSEN2 mutations, presenilin, amyloid precursor protein, novel mutations, de novo mutations, sporadic Alzheimer's disease, familial Alzheimer's disease, genetic screening, variant interpretation, cerebrospinal fluid biomarkers, total tau, phosphorylated tau, amyloid-beta 42, genetic counseling, mutation carriers
MeSH terms: Adult, Alzheimer Disease, Female, France, Genetic Testing, Humans, Male, Middle Aged, Mutation, Amyloid beta-Protein Precursor, Age of Onset, Presenilin-1, Presenilin-2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks